Update of Research on Drug Resistance in Small Cell Lung Cancer Chemotherapy

被引：49

作者：

Chen, Yi-Tian ^{[1
]}

Feng, Bing ^{[1
]}

Chen, Long-Bang ^{[1
]}

机构：

[1] Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

来源：

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2012年 / 13卷 / 08期

关键词：

Small cell lung cancer (SCLC); chemoresistance; targeted therapy; PHASE-II TRIAL; BCL-2; CARBOPLATIN; INHIBITION; EXPRESSION; PROTEINS; GROWTH; ETOPOSIDE; APOPTOSIS; THERAPY;

D O I：

10.7314/APJCP.2012.13.8.3577

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Small cell lung cancer (SCLC) is characterized by a short cell doubling time, rapid progression and early occurrence of blood-borne and lymph metastasis. The malignancy is the highest of all lung cancer types. Although SCLC has a relatively good initial response to chemotherapy as well as radiotherapy, relapse or disease progression may occur quickly after the initial treatment. Drug resistance, especially multi-drug resistance, is the most important cause of failure of SCLC chemotherapy. This article provides a brief update of research on mechanisms of drug resistance in SCLC and reversal strategies.

引用

页码：3577 / 3581

页数：5

共 35 条

[1]

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].

Antonia, SJ ;

Mirza, N ;

Fricke, I ;

Chiappori, A ;

Thompson, P ;

Williams, N ;

Bepler, G ;

Simon, G ;

Janssen, W ;

Lee, JH ;

Menander, K ;

Chada, S ;

Gabrilovich, DI .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887

[2]

Akt Requires Glucose Metabolism to Suppress Puma Expression and Prevent Apoptosis of Leukemic T Cells [J].

Coloff, Jonathan L. ;

Mason, Emily F. ;

Altman, Brian J. ;

Gerriets, Valerie A. ;

Liu, Tingyu ;

Nichols, Amanda N. ;

Zhao, Yuxing ;

Wofford, Jessica A. ;

Jacobs, Sarah R. ;

Ilkayeva, Olga ;

Garrison, Sean P. ;

Zambetti, Gerard P. ;

Rathmell, Jeffrey C. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (07) :5921-5933

[3]

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects [J].

Demedts, I. K. ;

Vermaelen, K. Y. ;

van Meerbeeck, J. P. .

EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (01) :202-215

[4]

Novel targets for lung cancer therapy: Part I [J].

Dy, GK ;

Adjei, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2881-2894

[5]

Molecular pathogenesis of lung cancer [J].

Fong, KM ;

Sekido, Y ;

Minna, JD .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (06) :1136-1152

[6]

Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome [J].

Gemba, K ;

Ueoka, H ;

Kiura, K ;

Tabata, M ;

Harada, M .

LUNG CANCER, 2000, 29 (01) :23-31

[7]

[关俊明 GUAN Junming], 2011, [广东医学, Guangdong Medical Journal], V32, P999

[8]

Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis [J].

Guo, Linlang ;

Liu, Yongguang ;

Bai, Yifeng ;

Sun, Yanqin ;

Xiao, Faman ;

Guo, Ying .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (09) :1692-1702

[9]

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer [J].

Hann, Christine L. ;

Daniel, Vincent C. ;

Sugar, Elizabeth A. ;

Dobromilskaya, Irina ;

Murphy, Sara C. ;

Cope, Leslie ;

Lin, Xue ;

Hierman, Jared S. ;

Wilburn, Daniel L. ;

Watkins, D. Neil ;

Rudin, Charles M. .

CANCER RESEARCH, 2008, 68 (07) :2321-2328

[10]

Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest [J].

Harley, Margaret E. ;

Allan, Lindsey A. ;

Sanderson, Helen S. ;

Clarke, Paul R. .

EMBO JOURNAL, 2010, 29 (14) :2407-2420

← 1 2 3 4 →